期刊文献+

不稳定型心绞痛应用欣维宁的疗效观察 被引量:4

在线阅读 下载PDF
导出
摘要 目的:观察不稳定性心绞痛患者在常规抗心绞痛(UAP)治疗基础上给予欣维宁治疗的疗效。方法:将UAP患者60例随机分为2组,即治疗组(常规治疗加欣维宁)和对照组(常规治疗),每组30例,2组年龄、性别、心绞痛发作类型、静息心电图情况、血压、血脂、血糖、体重指数情况比较无显著性差异。对照组予硝酸甘油持续静脉点滴72h,口服辛伐他汀、卡托普利、倍他乐克、阿斯匹林、波立维及克赛皮下注射,血压、血糖控制达标。治疗组予欣维宁静脉持续点滴72h,起始负荷剂量0.4μg/(kg·min)30min,而后0.1μg/(kg·min)静点,克赛减半,余治疗同对照组。结果:1周后总有效率治疗组86.7%,对照组60%,随防30d治疗组未出现严重不良反应(上消化道出血、脑出血、肉眼血尿、血小板减少),2例镜下血尿,4例牙龈出血。结论:欣维宁对不稳定型心绞痛有较好疗效和安全性。
作者 何晓雷
出处 《中国医药导报》 CAS 2007年第01Z期94-95,共2页 China Medical Herald
  • 相关文献

参考文献2

二级参考文献26

  • 1[1]Elmouchi DA,Bates ER.Platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in non-ST segment elevation acute coronary syndromes[J].Minerva Cardioangiol,2003,51 (5):547-560.
  • 2[2]Valgimigli M,Percoco G,Malagutti P,et al.Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial[J].JAMA,2005,293 (17):2109-2117.
  • 3[3]Heitzer,T Ollmann,I Koke,K et al.Platelet Glycoprotein Ⅱb/Ⅲa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease[J].Circulation,2003,108 (5):536-541.
  • 4[4]Warnholtz A,Ostad MA,Heitzer T,et al.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95 (1):20-23
  • 5[5]De Luca G,Smit JJ,Ernst N,et al.Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction[J].Thromb Haemost,2005,93 (5):820-823.
  • 6[6]Martinez-Rios MA,Rosas M,Gonzalez H,et al.Comparison of reperfusion regimens with or without tirofiban in STelevation acute myocardial infarction[J].Am J Cardiol,2004,93 (3):280-287.
  • 7[7]Lavi S,Gruberg L,Kapeliovich M,et al.The impact of GP Ⅱb/Ⅲa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients[J].J Invasive Cardiol,2005,17 (6):296-299.
  • 8[8]Roffi M,Chew DP,Mukherjee D,et al.Platelet glycoprotein Ⅱb/Ⅲa inhibition in acute coronary syndromes.Gradient of benefit related to the revascularization strategy[J].Eur Heart J,2002,23 (18):1441-1448.
  • 9[9]Sabatine MS,Morrow DA,Giugliano RP,et al.Implications of upstream glycoprotein Ⅱb/Ⅲa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction:a comparison of the Thrombolysis In Myocardial Infarction (TIMI) ⅢB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial[J].Circulation,2004,109 (7):874-880.
  • 10[10]Marsh JD.Early use of glycoprotein Ⅱb/Ⅲa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes[J].Am J Health Syst Pharm,2002,59 (21 Suppl 7):S15-S26.

共引文献87

同被引文献19

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部